FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL						
OMB Number:	3235-0287					
Estimated average bur	den hours					
per response	0.5					

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

 $\label{eq:company} Filed \ pursuant \ to \ Section \ 16(a) \ of \ the \ Securities \ Exchange \ Act \ of \ 1934 \ or \ Section \ 30(h) \ of \ the \ Investment \ Company \ Act \ of \ 1940$

(Print or Type Res	sponses)																	
Name and Address of Reporting Person * Chin Mark				2. Issuer Name and Ticker or Trading Symbol Iterum Therapeutics plc [ITRM]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner							
(Last) (First) (Middle) C/O ITERUM THERAPEUTICS PLC, BLK 2, FL. 3, HARCOURT CENTRE, HARCOURT ST.				3. Date of Earliest Transaction (Month/Day/Year) 04/07/2020								Officer (give titl	e below)	Otl	ner (specify bel	ow)		
(Street) DUBLIN, L2 2				4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing(Check Applicable Line) X. Form filed by One Reporting Person Form filed by More than One Reporting Person							
(City) (State) (Zip)				Table I - Non-Derivative Securities Acqui							uired,	ired, Disposed of, or Beneficially Owned						
1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year		2A. Deemed Execution Date, is any (Month/Day/Year			(Instr. 8)	4. Securities Acquired (or Disposed of (D) (Instr. 3, 4 and 5)		Owned Follo Transaction(s		ed Following action(s)				7. Nature of Indirect Beneficial Ownership				
				(Month)	Баул	i car)	Code	V	Amo	ount	(A) or (D)	Price	,			Direct (D) or Indirect (I) (Instr. 4)	1	
Ordinary Shar	es		04/07/2020				J <u>(1)</u>	V	1,089	,903	D	<u>(1)</u>	0			I	By Arix Bioscience Holdings Ltd. (2)	
Ordinary Shares											6,154			Γ		D		
Reminder: Report	t on a separat	e line for each class	of securities benefi	I - Deriv	ative	Secu	rities Acqui	Per this cur	form a rently v	are no valid C I of, or	ot requir DMB co Benefic	red to entrol i	resp numb				n Si	EC 1474 (9-02)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)		4. 5. Nu Transaction Code Secu (Instr. 8) Acqu Disposition		umber of	ptions, convertible securitie 6. Date Exercisable and Expiration Date (Month/Day/Year)		1			Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported	Owner Form o	Ownership (Instr. 4)			
				Code	V	(A)	(D)	Date Exer	cisable	Expira Date	ation	Title		Amount or Number of Shares		Transaction(s (Instr. 4)	(I) (Instr. 4	1)
6.500% Exchangeable Senior Subordinated Note due 2025	(1)	04/07/2020		J ⁽¹⁾	V		\$ 1,900,000		<u>(1)</u>	01/31	1/2025	Ordii Sha	-	1,900,000	(1)	0	I	By Arix Bioscience Holdings Ltd. (2)

Reporting Owners

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Chin Mark C/O ITERUM THERAPEUTICS PLC, BLK 2 FL. 3, HARCOURT CENTRE, HARCOURT ST. DUBLIN, L2 2	X						

Signatures

/s/ Mark Chin	04/09/2020
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) On April 7, 2020, the reporting person resigned as an investment director for Arix Bioscience plc, which is the sole owner and parent of Arix Bioscience Holdings Ltd., which holds these securities. As a result of his resignation, the reporting person no longer has any voting power over these securities and therefore has ceased to beneficially own such securities.

(2) Arix Bioscience Holdings Ltd. continues to hold these securities.

 $Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, {\it see}\ Instruction\ 6 for procedure.$

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.